Title of article :
Characteristics of the human endometrial regeneration cells as a potential source for future stem cell-based therapies: A lab resources study
Author/Authors :
Akyash, Fatemeh Stem Cell Biology Research Center - Yazd Reproductive Sciences Institute - Shahid Sadoughi University of Medical Sciences, Yazd, Iran , Javidpou, Mahdieh Stem Cell Biology Research Center - Yazd Reproductive Sciences Institute - Shahid Sadoughi University of Medical Sciences, Yazd, Iran , Farashahi Yazd, Ehsan Stem Cell Biology Research Center - Yazd Reproductive Sciences Institute - Shahid Sadoughi University of Medical Sciences, Yazd, Iran , Golzadeh, Jalal Stem Cell Biology Research Center - Yazd Reproductive Sciences Institute - Shahid Sadoughi University of Medical Sciences, Yazd, Iran , Hajizadeh-Tafti, Fatemeh Stem Cell Biology Research Center - Yazd Reproductive Sciences Institute - Shahid Sadoughi University of Medical Sciences, Yazd, Iran , Aflatoonian, Reza Department of Endocrinology and Female Infertility - Reproductive Biomedicine Research Center - Royan Institute for Reproductive Biomedicine, ACECR, Tehran, Iran , Aflatoonian, Behrouz Stem Cell Biology Research Center - Yazd Reproductive Sciences Institute - Shahid Sadoughi University of Medical Sciences, Yazd, Iran
Abstract :
Background: Human endometrium with consecutive regeneration capability
undergoes monthly hormonal changes for probable implantation, which confirms
the presence of the cells in the basalis layer known as stem cell.
Objective: Previously, we reported the isolation and culture of the mesenchymal-like
cells from human endometrium. In this study, we evaluated the biological and stemness
characteristics of these cells.
Materials and Methods: The characterization of Yazd human endometrialderived
mesenchymal stem/stromal cells (YhEnMSCs) was assessed using
immunofluorescence (IF) staining for CD105, VIMENTIN, and FIBRONECTIN as
markers and RT-PCR for CD166, CD10, CD105, VIMENTIN, FIBRONECTIN, MHCI, CD14,
and MHCII genes. Flow cytometry (FACS) was performed for CD44, CD73, CD90,
and CD105 markers. Moreover, the differentiation capacity of the YhEnMSCs to the
osteoblast and adipocytes was confirmed by Alizarin Red and Oil Red staining.
Results: YhEnMSCs expressed CD105, VIMENTIN, FIBRONECTIN, CD44, CD73, and
CD90 markers and CD166, CD10, CD105, VIMENTIN, FIBRONECTIN, and MHCI, but,
did not express CD14, MHCII.
Conclusion: Our data confirm previous reports by other groups indicating the
application of endometrial cells as an available source of MSCs with self-renewal and
differentiation capacity. Accordingly, YhEnMSCs can be used as a suitable source for
cell-based therapies.
Keywords :
Cell-based therapy , Endometrium , Mesenchymal stem/stromal cells , Regenerative medicine , Stem cells , Uterus
Journal title :
International Journal of Reproductive BioMedicine